| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
(2R)-3-(((2-Aminoethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl ditetradecanoate targets cell membranes and lipid bilayers. As a phospholipid (1,2-DMPE), it is involved in membrane structure, lipid signaling, and cellular function. Its "target" in research is the study of membrane biophysics, lipid metabolism, and phospholipid biology.
|
|---|---|
| ln Vitro |
In vitro, this compound is used to study lipid bilayer formation and membrane properties. As a phospholipid, it is a component of cell membranes. Its activity is measured by assessing membrane fluidity, bilayer stability, and lipid-protein interactions in model membrane systems.
|
| ln Vivo |
In vivo, this compound is an endogenous metabolite and a phospholipid involved in membrane structure and lipid metabolism. As 1,2-DMPE, it is a component of cell membranes. It is not a therapeutic agent but is studied in the context of lipid metabolism and membrane biology.
|
| Enzyme Assay |
In vitro enzyme assays with this compound typically involve studying phospholipases, acyltransferases, or other lipid-metabolizing enzymes. The compound is used as a substrate to measure enzyme activity. Standard assays involve incubating the phospholipid with enzyme preparations and measuring the release of fatty acids or lysophospholipid products by chromatographic methods.
|
| Cell Assay |
In vitro cell culture experiments with this compound involve treating various cell types to study lipid metabolism and membrane function. Cells are treated with the phospholipid, and endpoints include assessment of cell proliferation, membrane fluidity, and signaling pathway activation. These experiments characterize the biological effects of phospholipids.
|
| Animal Protocol |
In vivo animal experiments with this compound typically involve administering the compound to animal models of lipid metabolism disorders. Key endpoints include assessment of plasma lipid levels, inflammatory markers, and histopathological examination of tissues. These studies investigate the role of phospholipids in lipid metabolism and disease pathogenesis.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of this compound reflect its role as a lipid. It is present in plasma lipoproteins and cell membranes. As a phospholipid, it is metabolized by phospholipases and acyltransferases. Its levels in plasma and tissues reflect lipid metabolism. It has a purity of 97%.
|
| Toxicity/Toxicokinetics |
This compound has a low toxicity profile as a naturally occurring phospholipid. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance. Comprehensive toxicology studies have not been published for this compound.
|
| Additional Infomation |
PE (14:0/14:0) is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain).
(2R)-3-(((2-Aminoethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl ditetradecanoate (1,2-Dimyristoyl-sn-glycero-3-Phosphoethanolamine, 1,2-DMPE) is an endogenous metabolite and a phospholipid consisting of two myristoyl chains. It is used in membrane biophysics and lipid metabolism research. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only. |
| Molecular Formula |
C33H66NO8P
|
|---|---|
| Molecular Weight |
635.86
|
| Exact Mass |
635.452
|
| CAS # |
998-07-2
|
| Related CAS # |
(2R)-3-(((2-Aminoethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl ditetradecanoate-d54;326495-41-4
|
| PubChem CID |
9852308
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
685.6±65.0 °C at 760 mmHg
|
| Melting Point |
193 °C
|
| Flash Point |
368.5±34.3 °C
|
| Vapour Pressure |
0.0±4.6 mmHg at 25°C
|
| Index of Refraction |
1.474
|
| LogP |
11.58
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
35
|
| Heavy Atom Count |
43
|
| Complexity |
694
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC
|
| InChi Key |
NEZDNQCXEZDCBI-WJOKGBTCSA-N
|
| InChi Code |
InChI=1S/C33H66NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-32(35)39-29-31(30-41-43(37,38)40-28-27-34)42-33(36)26-24-22-20-18-16-14-12-10-8-6-4-2/h31H,3-30,34H2,1-2H3,(H,37,38)/t31-/m1/s1
|
| Chemical Name |
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 3.33 mg/mL (5.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5727 mL | 7.8634 mL | 15.7267 mL | |
| 5 mM | 0.3145 mL | 1.5727 mL | 3.1453 mL | |
| 10 mM | 0.1573 mL | 0.7863 mL | 1.5727 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
